University of Vermont

College of Medicine

Department of Medicine


Bio for Claire Verschraegen, M.D., M.S.
Claire Verschraegen, M.D., M.S.

Claire Verschraegen, M.D., M.S.

Professor of Medicine
Director, Hematology/Oncology Division
Department of Medicine

Contact Information
Office Location:
Hematology/Oncology Division, UVM Given Building, Suite E214, 89 Beaumont Avenue, Burlington, VT 05405


Universite Libre de Bruxelles, Brussels, Belgium, MS (Botany), 1977-1980
Universite Libre de Bruxelles, Brussels, Belgium, MD, 1975-1982

Postdoctoral Training

Université Libre de Bruxelles, Brussels, Belgium, Postgraduate Degree - Internal Medicine/Oncology Specialty, 1982-1987
Research Fellowship, Stehlin Foundation for Cancer Research, 1985-1988
The University of Texas Health Science Center Houston, TX - Residency in Internal Medicine, 1988-1991
The University of Texas M. D. Anderson Cancer Center Houston, TX, Fellowship in Medical Oncology, 1992-1994

Academic Appointments

Professor of Medicine

Director, Cancer Clinic University of Vermont Medical Center

Deputy Director for Clinical Affairs, Cancer Service Line, University of Vermont Cancer Center

Certification/Board Eligibility

American Board of Internal Medicine, Internal Medicine, 1991, Recertification 2000
American Board of Internal Medicine, Medical Oncology, 1995, Recertification 2000
Accredited by Belgian royal decree as Specialist Physician, 1992

Professional Societies

American Society of Clinical Oncology
International Society for Gynecologic Oncology
American College of Physicians
Connective Tissue Oncology Society
Member of cooperative cancer groups (GOG, SWOG, NCCTG, ACOSOG)


Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst. 2004 Jan 21;96(2):115-21. PubMed PMID: 14734701.

Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, Verschraegen CF. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54.

O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Aug;21(8):1712-7. Epub 2010 Feb 10.PMID: 20147741.

Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C. Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol. 2011 Oct;22(10):2166-78.

Verschraegen CF, Arias-Pulido H, Lee SJ, et al: Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol, 2011 [Epub ahead of print]

For a complete list of Claire Verschraegen's publications, please visit Google Scholar.